Stock Scorecard
Stock Summary for Candel Therapeutics Inc (CADL) - $9.85 as of 7/24/2026 7:35:11 PM EST
Total Score
8 out of 30
Safety Score
31 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CADL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CADL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CADL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CADL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CADL (31 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 2 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CADL
Financial Details for CADL
Company Overview |
|
|---|---|
| Ticker | CADL |
| Company Name | Candel Therapeutics Inc |
| Country | USA |
| Description | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/13/2026 |
Stock Price History |
|
| Last Day Price | 9.85 |
| Price 4 Years Ago | 1.79 |
| Last Day Price Updated | 7/24/2026 7:35:11 PM EST |
| Last Day Volume | 766,392 |
| Average Daily Volume | 1,849,489 |
| 52-Week High | 11.36 |
| 52-Week Low | 4.35 |
| Last Price to 52 Week Low | 126.44% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 111.02 |
| Sector PE | 88.41 |
| 5-Year Average PE | -18.70 |
| Free Cash Flow Ratio | 3.70 |
| Industry Free Cash Flow Ratio | 17.54 |
| Sector Free Cash Flow Ratio | 29.81 |
| Current Ratio Most Recent Quarter | 28.05 |
| Total Cash Per Share | 2.66 |
| Book Value Per Share Most Recent Quarter | 1.88 |
| Price to Book Ratio | 3.29 |
| Industry Price to Book Ratio | 12.43 |
| Sector Price to Book Ratio | 11.88 |
| Price to Sales Ratio Twelve Trailing Months | 436.42 |
| Industry Price to Sales Ratio Twelve Trailing Months | 9.31 |
| Sector Price to Sales Ratio Twelve Trailing Months | 4.99 |
| Analyst Buy Ratings | 7 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 73,270,000 |
| Market Capitalization | 721,709,500 |
| Institutional Ownership | 60.21% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 30.80% |
| Reported EPS 12 Trailing Months | -0.99 |
| Reported EPS Past Year | -0.14 |
| Reported EPS Prior Year | -0.46 |
| Net Income Twelve Trailing Months | -54,422,000 |
| Net Income Past Year | -38,182,000 |
| Net Income Prior Year | -55,177,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 194,834,000 |
| Total Cash Past Year | 119,731,000 |
| Total Cash Prior Year | 102,654,000 |
| Net Cash Position Most Recent Quarter | 147,359,000 |
| Net Cash Position Past Year | 72,601,000 |
| Long Term Debt Past Year | 47,130,000 |
| Long Term Debt Prior Year | 2,603,000 |
| Total Debt Most Recent Quarter | 47,475,000 |
| Equity to Debt Ratio Past Year | 0.52 |
| Equity to Debt Ratio Most Recent Quarter | 0.74 |
| Total Stockholder Equity Past Year | 51,922,000 |
| Total Stockholder Equity Prior Year | 66,327,000 |
| Total Stockholder Equity Most Recent Quarter | 138,029,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -48,991,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.67 |
| Free Cash Flow Past Year | -38,898,000 |
| Free Cash Flow Prior Year | -27,039,000 |
Options |
|
| Put/Call Ratio | 80.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | -0.51 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 7/24/2026 2:42:59 PM EST |